You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameOxymorphone
Accession NumberDB01192  (APRD00158)
TypeSmall Molecule
GroupsApproved, Investigational, Vet Approved
DescriptionAn opioid analgesic with actions and uses similar to those of morphine, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092)
Structure
Thumb
Synonyms
14-Hydroxydihydromorphinone
Dihydrohydroxymorphinone
Dihydroxymorphinone
EN3202
Numorphan
Opana
Oximorphonum
Oxymorphine
Oxymorphone
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Numorphan Injection 1.5mg/mlLiquid1.5 mgIntramuscular; Intravenous; SubcutaneousBristol Myers Squibb Canada1993-12-312004-08-04Canada
Numorphan Suppository 5mgSuppository5 mgRectalBristol Myers Squibb Canada1993-12-312002-07-04Canada
OpanaTablet5 mg/1OralEndo Pharmaceuticals2006-06-26Not applicableUs
OpanaTablet5 mg/1Oralbryant ranch prepack2006-06-26Not applicableUs
OpanaTablet5 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-02-09Not applicableUs
OpanaTablet10 mg/1OralEndo Pharmaceuticals2006-06-26Not applicableUs
OpanaTablet10 mg/1OralSTAT Rx USA LLC2011-12-15Not applicableUs
OpanaTablet10 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-02-09Not applicableUs
OpanaInjection1 mg/mLIntramuscular; Intravenous; SubcutaneousEndo Pharmaceuticals Inc.1959-06-01Not applicableUs
Opana ERTablet, extended release10 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-10Not applicableUs
Opana ERTablet, extended release15 mg/1OralEndo Pharmaceuticals Inc.2012-03-20Not applicableUs
Opana ERTablet, film coated, extended release40 mg/1OralSTAT Rx USA LLC2006-06-22Not applicableUs
Opana ERTablet, extended release30 mg/1OralLake Erie Medical DBA Quality Care Products LLC2012-03-20Not applicableUs
Opana ERTablet, extended release40 mgOralPaladin Labs IncNot applicableNot applicableCanada
Opana ERTablet, extended release5 mg/1OralEndo Pharmaceuticals Inc.2012-03-20Not applicableUs
Opana ERTablet, film coated, extended release5 mg/1OralRebel Distributors Corp2006-06-22Not applicableUs
Opana ERTablet, extended release20 mg/1OralEndo Pharmaceuticals Inc.2012-03-20Not applicableUs
Opana ERTablet, extended release20 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-10Not applicableUs
Opana ERTablet, film coated, extended release10 mg/1OralSTAT Rx USA LLC2006-06-22Not applicableUs
Opana ERTablet, extended release5 mgOralPaladin Labs IncNot applicableNot applicableCanada
Opana ERTablet20 mg/1Oralbryant ranch prepack2010-12-31Not applicableUs
Opana ERTablet, extended release10 mg/1OralLake Erie Medical DBA Quality Care Products LLC2012-03-20Not applicableUs
Opana ERTablet, extended release7.5 mg/1OralEndo Pharmaceuticals Inc.2012-03-20Not applicableUs
Opana ERTablet, film coated, extended release10 mg/1OralRebel Distributors Corp2006-06-22Not applicableUs
Opana ERTablet, extended release30 mg/1OralEndo Pharmaceuticals Inc.2012-03-20Not applicableUs
Opana ERTablet, extended release40 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-02-14Not applicableUs
Opana ERTablet20 mg/1OralSt Marys Medical Park Pharmacy2010-12-31Not applicableUs
Opana ERTablet, extended release10 mgOralPaladin Labs IncNot applicableNot applicableCanada
Opana ERTablet, extended release40 mg/1Oralbryant ranch prepack2006-06-30Not applicableUs
Opana ERTablet, extended release20 mg/1OralLake Erie Medical DBA Quality Care Products LLC2012-03-20Not applicableUs
Opana ERTablet, extended release10 mg/1OralEndo Pharmaceuticals Inc.2012-03-20Not applicableUs
Opana ERTablet, extended release40 mg/1OralEndo Pharmaceuticals Inc.2012-03-20Not applicableUs
Opana ERTablet, extended release30 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-02-14Not applicableUs
Opana ERTablet, film coated, extended release5 mg/1OralSTAT Rx USA LLC2006-06-22Not applicableUs
Opana ERTablet, extended release20 mgOralPaladin Labs IncNot applicableNot applicableCanada
Opana ERTablet, extended release40 mg/1OralLake Erie Medical DBA Quality Care Products LLC2012-03-20Not applicableUs
Oxymorphone HydrochlorideTablet10 mg/1OralAmerican Health Packaging2015-12-21Not applicableUs
Oxymorphone HydrochlorideTablet5 mg/1OralQualitest Pharmaceuticals2010-09-29Not applicableUs
Oxymorphone HydrochlorideTablet10 mg/1OralQualitest Pharmaceuticals2010-09-29Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Oxymorphone HydrochlorideTablet10 mg/1OralAurolife Pharma, LLC2016-04-26Not applicableUs
Oxymorphone HydrochlorideTablet10 mg/1OralCore Pharma, Llc2015-01-17Not applicableUs
Oxymorphone HydrochlorideTablet, extended release7.5 mg/1OralActavis Pharma, Inc.2010-12-31Not applicableUs
Oxymorphone HydrochlorideTablet5 mg/1OralMallinckrodt, Inc.2012-04-12Not applicableUs
Oxymorphone HydrochlorideTablet, film coated, extended release40 mg/1OralImpax Generics2013-01-02Not applicableUs
Oxymorphone HydrochlorideTablet, film coated, extended release7.5 mg/1OralRanbaxy Pharmaceuticals Inc.2015-04-13Not applicableUs
Oxymorphone HydrochlorideTablet10 mg/1OralTeva Pharmaceuticals Usa, Inc.2013-04-11Not applicableUs
Oxymorphone HydrochlorideTablet10 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-11-29Not applicableUs
Oxymorphone HydrochlorideTablet, extended release5 mg/1OralActavis Pharma, Inc.2010-12-31Not applicableUs
Oxymorphone HydrochlorideTablet5 mg/1OralLake Erie Medical DBA Quality Care Products LLC2013-02-11Not applicableUs
Oxymorphone HydrochlorideTablet, film coated, extended release30 mg/1OralRanbaxy Pharmaceuticals Inc.2015-04-13Not applicableUs
Oxymorphone HydrochlorideTablet, film coated, extended release30 mg/1OralLake Erie Medical DBA Quality Care Products LLC2013-01-02Not applicableUs
Oxymorphone HydrochlorideTablet5 mg/1OralWest Ward Pharmaceuticals Corp.2010-09-27Not applicableUs
Oxymorphone HydrochlorideTablet, film coated, extended release20 mg/1OralLake Erie Medical DBA Quality Care Products LLC2013-01-02Not applicableUs
Oxymorphone HydrochlorideTablet, film coated, extended release10 mg/1OralRanbaxy Pharmaceuticals Inc.2015-04-13Not applicableUs
Oxymorphone HydrochlorideTablet, extended release15 mg/1OralActavis Pharma, Inc.2010-12-31Not applicableUs
Oxymorphone HydrochlorideTablet10 mg/1OralMallinckrodt, Inc.2012-04-12Not applicableUs
Oxymorphone HydrochlorideTablet, film coated, extended release7.5 mg/1OralImpax Generics2013-01-02Not applicableUs
Oxymorphone HydrochlorideTablet, extended release10 mg/1OralActavis Pharma, Inc.2010-12-31Not applicableUs
Oxymorphone HydrochlorideTablet, film coated, extended release5 mg/1OralImpax Generics2013-01-02Not applicableUs
Oxymorphone HydrochlorideTablet, extended release15 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-12-31Not applicableUs
Oxymorphone HydrochlorideTablet10 mg/1OralLake Erie Medical DBA Quality Care Products LLC2013-02-11Not applicableUs
Oxymorphone HydrochlorideTablet, film coated, extended release40 mg/1OralRanbaxy Pharmaceuticals Inc.2015-04-13Not applicableUs
Oxymorphone HydrochlorideTablet, film coated, extended release5 mg/1OralLake Erie Medical DBA Quality Care Products LLC2013-01-02Not applicableUs
Oxymorphone HydrochlorideTablet10 mg/1OralWest Ward Pharmaceuticals Corp.2010-09-27Not applicableUs
Oxymorphone HydrochlorideTablet5 mg/1OralKvk Tech, Inc.2013-02-11Not applicableUs
Oxymorphone HydrochlorideTablet, film coated, extended release40 mg/1OralLake Erie Medical DBA Quality Care Products LLC2013-01-02Not applicableUs
Oxymorphone HydrochlorideTablet, film coated, extended release15 mg/1OralRanbaxy Pharmaceuticals Inc.2015-04-13Not applicableUs
Oxymorphone HydrochlorideTablet, extended release30 mg/1OralActavis Pharma, Inc.2010-12-31Not applicableUs
Oxymorphone HydrochlorideTablet, film coated, extended release15 mg/1OralImpax Generics2013-01-02Not applicableUs
Oxymorphone HydrochlorideTablet, extended release20 mg/1OralActavis Pharma, Inc.2010-12-31Not applicableUs
Oxymorphone HydrochlorideTablet, film coated, extended release10 mg/1OralImpax Generics2013-01-02Not applicableUs
Oxymorphone HydrochlorideTablet10 mg/1OralPhysicians Total Care, Inc.2012-12-10Not applicableUs
Oxymorphone HydrochlorideTablet5 mg/1OralAurolife Pharma, LLC2016-04-26Not applicableUs
Oxymorphone HydrochlorideTablet5 mg/1OralCore Pharma, Llc2015-01-17Not applicableUs
Oxymorphone HydrochlorideTablet5 mg/1OralTeva Pharmaceuticals Usa, Inc.2013-04-11Not applicableUs
Oxymorphone HydrochlorideTablet10 mg/1OralKvk Tech, Inc.2013-02-11Not applicableUs
Oxymorphone HydrochlorideTablet, film coated, extended release10 mg/1OralLake Erie Medical DBA Quality Care Products LLC2013-01-02Not applicableUs
Oxymorphone HydrochlorideTablet, film coated, extended release20 mg/1OralRanbaxy Pharmaceuticals Inc.2015-04-13Not applicableUs
Oxymorphone HydrochlorideTablet, film coated, extended release15 mg/1OralLake Erie Medical DBA Quality Care Products LLC2013-01-02Not applicableUs
Oxymorphone HydrochlorideTablet, film coated, extended release30 mg/1OralImpax Generics2013-01-02Not applicableUs
Oxymorphone HydrochlorideTablet, film coated, extended release5 mg/1OralRanbaxy Pharmaceuticals Inc.2015-04-13Not applicableUs
Oxymorphone HydrochlorideTablet, extended release40 mg/1OralActavis Pharma, Inc.2010-12-31Not applicableUs
Oxymorphone HydrochlorideTablet, film coated, extended release20 mg/1OralImpax Generics2013-01-02Not applicableUs
Oxymorphone Hydrochloride Extended-releaseTablet, extended release15 mg/1OralMallinckrodt, Inc.2014-06-27Not applicableUs
Oxymorphone Hydrochloride Extended-releaseTablet, extended release20 mg/1OralMallinckrodt, Inc.2014-06-27Not applicableUs
Oxymorphone Hydrochloride Extended-releaseTablet, extended release30 mg/1OralMallinckrodt, Inc.2014-06-27Not applicableUs
Oxymorphone Hydrochloride Extended-releaseTablet, extended release40 mg/1OralMallinckrodt, Inc.2014-06-27Not applicableUs
Oxymorphone Hydrochloride Extended-releaseTablet, extended release5 mg/1OralMallinckrodt, Inc.2014-06-27Not applicableUs
Oxymorphone Hydrochloride Extended-releaseTablet, extended release7.5 mg/1OralMallinckrodt, Inc.2014-06-27Not applicableUs
Oxymorphone Hydrochloride Extended-releaseTablet, extended release10 mg/1OralMallinckrodt, Inc.2014-06-27Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
NumorphanNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Oxymorphone hydrochloride
357-07-3
Thumb
  • InChI Key: BCGJBQBWUGVESK-KCTCKCTRSA-N
  • Monoisotopic Mass: 337.1080858
  • Average Mass: 337.8
DBSALT001249
Categories
UNII9VXA968E0C
CAS number76-41-5
WeightAverage: 301.3371
Monoisotopic: 301.131408101
Chemical FormulaC17H19NO4
InChI KeyUQCNKQCJZOAFTQ-ISWURRPUSA-N
InChI
InChI=1S/C17H19NO4/c1-18-7-6-16-13-9-2-3-10(19)14(13)22-15(16)11(20)4-5-17(16,21)12(18)8-9/h2-3,12,15,19,21H,4-8H2,1H3/t12-,15+,16+,17-/m1/s1
IUPAC Name
(1S,5R,13R,17S)-10,17-dihydroxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7(18),8,10-trien-14-one
SMILES
[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1(O)CCC2=O
Pharmacology
IndicationFor the treatment of moderate-to-severe pain.
Structured Indications
PharmacodynamicsOxymorphone is a semi-synthetic opioid substitute for morphine. It is a potent analgesic. Opioid analgesics exert their principal pharmacologic effects on the CNS and the gastrointestinal tract. The principal actions of therapeutic value are analgesia and sedation. Opioids produce respiratory depression by direct action on brain stem respiratory centers. The mechanism of respiratory depression involves a reduction in the responsiveness of the brain stem respiratory centers to increases in carbon dioxide tension and to electrical stimulation.
Mechanism of actionOxymorphone interacts predominantly with the opioid mu-receptor. These mu-binding sites are discretely distributed in the human brain, with high densities in the posterior amygdala, hypothalamus, thalamus, nucleus caudatus, putamen, and certain cortical areas. They are also found on the terminal axons of primary afferents within laminae I and II (substantia gelatinosa) of the spinal cord and in the spinal nucleus of the trigeminal nerve. Also, it has been shown that oxymorphone binds to and inhibits GABA inhibitory interneurons via mu-receptors. These interneurons normally inhibit the descending pain inhibition pathway. So, without the inhibitory signals, pain modulation can proceed downstream.
TargetKindPharmacological actionActionsOrganismUniProt ID
Mu-type opioid receptorProteinyes
agonist
HumanP35372 details
Delta-type opioid receptorProteinunknown
antagonist
HumanP41143 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Oxymorphone undergoes extensive hepatic metabolism in humans. After a 10 mg oral dose, 49% was excreted over a five-day period in the urine. Of this, 82% was excreted in the first 24 hours after administration. The recovered drug-related products contained the oxymorphone (1.9%), the conjugate of oxymorphone (44.1%), the 6(beta)-carbinol produced by 6-keto reduction of oxymorphone (0.3%), and the conjugates of 6(beta)-carbinol (2.6%) and 6(alpha)-carbinol (0.1%).

SubstrateEnzymesProduct
Oxymorphone
noroxycodoneDetails
Oxymorphone
noroxymorphoneDetails
Oxymorphone
alpha-noroxycodolDetails
Oxymorphone
beta-noroxycodolDetails
Oxymorphone
oxymorphoneDetails
Oxymorphone
beta-oxymorpholDetails
Oxymorphone
alpha-oxycodolDetails
Oxymorphone
beta-oxycodolDetails
Route of eliminationOxymorphone is highly metabolized, principally in the liver, and undergoes reduction or conjugation with glucuronic acid to form both active and inactive products. Because oxymorphone is extensively metabolized, <1% of the administered dose is excreted unchanged in the urine.
Half life1.3 (+/-0.7) hours
ClearanceNot Available
ToxicityOxymorphone overdosage is characterized by respiratory depression, extreme somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, and sometimes bradycardia and hypotension. In a severe case of overdose, apnea, circulatory collapse, cardiac arrest, and death may occur. Intravenous mouse LD50 is 172 mg/kg.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Oxymorphone Action PathwayDrug actionSMP00412
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with 1,1,1,2 Tetrafluoroethane.Investigational
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Oxymorphone.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Oxymorphone.Experimental, Illicit
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Oxymorphone.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Oxymorphone.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Oxymorphone is combined with 7-Nitroindazole.Experimental
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEThe risk or severity of adverse effects can be increased when Oxymorphone is combined with 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE.Experimental
AbirateroneThe serum concentration of Oxymorphone can be increased when it is combined with Abiraterone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Aceprometazine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Acetazolamide.Approved, Vet Approved
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Oxymorphone.Approved
adipiplonThe risk or severity of adverse effects can be increased when Oxymorphone is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Agomelatine.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Oxymorphone.Approved, Illicit
AlimemazineAlimemazine may increase the hypotensive activities of Oxymorphone.Approved, Vet Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Oxymorphone.Approved, Illicit, Investigational
AlvimopanThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Alvimopan.Approved
AmilorideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Amiloride.Approved
AmiodaroneThe metabolism of Oxymorphone can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Amitriptyline.Approved
Ammonium chlorideAmmonium chloride may increase the excretion rate of Oxymorphone which could result in a lower serum level and potentially a reduction in efficacy.Approved, Vet Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Amperozide.Experimental
AmphetamineAmphetamine may increase the analgesic activities of Oxymorphone.Approved, Illicit
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Oxymorphone.Approved
AprepitantThe serum concentration of Oxymorphone can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Aripiprazole.Approved, Investigational
ArtemetherThe metabolism of Oxymorphone can be decreased when combined with Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Asenapine.Approved
AtazanavirThe metabolism of Oxymorphone can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Oxymorphone can be decreased when combined with Atomoxetine.Approved
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Oxymorphone.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Oxymorphone.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Azaperone.Vet Approved
AzelastineOxymorphone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Azelastine.Approved
AzosemideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Azosemide.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Barbital.Illicit
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Oxymorphone.Withdrawn
BendroflumethiazideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Bendroflumethiazide.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Benperidol.Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Oxymorphone.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Oxymorphone.Approved
BenzphetamineBenzphetamine may increase the analgesic activities of Oxymorphone.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Benzyl alcohol.Approved
BetaxololThe metabolism of Oxymorphone can be decreased when combined with Betaxolol.Approved
BexaroteneThe serum concentration of Oxymorphone can be decreased when it is combined with Bexarotene.Approved, Investigational
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Oxymorphone.Approved
BL-1020BL-1020 may increase the hypotensive activities of Oxymorphone.Investigational
BoceprevirThe metabolism of Oxymorphone can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Oxymorphone can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Oxymorphone can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Oxymorphone.Approved
BromazepamThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Bromazepam.Approved, Illicit
BrompheniramineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Brotizolam.Approved, Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Oxymorphone.Approved, Investigational
BuprenorphineOxymorphone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Oxymorphone can be decreased when combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Oxymorphone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Oxymorphone.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Butethal.Approved, Illicit
ButorphanolButorphanol may decrease the analgesic activities of Oxymorphone.Approved, Illicit, Vet Approved
Canrenoic acidThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Canrenoic acid.Approved, Withdrawn
CanrenoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Canrenone.Investigational
CarbamazepineThe metabolism of Oxymorphone can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Carisoprodol.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Caroxazone.Withdrawn
CelecoxibThe metabolism of Oxymorphone can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Oxymorphone can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Oxymorphone.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Oxymorphone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Oxymorphone.Approved
ChloroquineThe metabolism of Oxymorphone can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Chlorphenamine.Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Oxymorphone.Withdrawn
ChlorphentermineChlorphentermine may increase the analgesic activities of Oxymorphone.Illicit, Withdrawn
ChlorpromazineThe metabolism of Oxymorphone can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Oxymorphone can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CicletanineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Cicletanine.Investigational
CimetidineThe metabolism of Oxymorphone can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Oxymorphone can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Oxymorphone.Approved, Vet Approved
CitalopramThe metabolism of Oxymorphone can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Oxymorphone can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Oxymorphone can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Clidinium.Approved
ClobazamThe metabolism of Oxymorphone can be decreased when combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Oxymorphone is combined with clomethiazole.Investigational
ClomipramineThe metabolism of Oxymorphone can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Oxymorphone.Approved, Illicit
ClotrimazoleThe metabolism of Oxymorphone can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Oxymorphone can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Oxymorphone can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Oxymorphone can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Oxymorphone.Approved, Illicit
ConivaptanThe serum concentration of Oxymorphone can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Oxymorphone can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Oxymorphone.Approved
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Oxymorphone.Approved
CyclosporineThe metabolism of Oxymorphone can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Cyclothiazide.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Cyproheptadine.Approved
DabrafenibThe serum concentration of Oxymorphone can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Oxymorphone.Approved
DapoxetineOxymorphone may increase the serotonergic activities of Dapoxetine.Investigational
DarifenacinThe metabolism of Oxymorphone can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Oxymorphone can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Oxymorphone can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Oxymorphone can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Oxymorphone can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Oxymorphone.Approved
DesipramineThe metabolism of Oxymorphone can be decreased when combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Desmopressin.Approved
DesvenlafaxineOxymorphone may increase the serotonergic activities of Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Oxymorphone can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Dexbrompheniramine.Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Oxymorphone.Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Oxymorphone.Approved, Vet Approved
DextroamphetamineDextroamphetamine may increase the analgesic activities of Oxymorphone.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Oxymorphone.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Oxymorphone.Approved, Illicit, Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Oxymorphone.Approved
DiethylpropionDiethylpropion may increase the analgesic activities of Oxymorphone.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe metabolism of Oxymorphone can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Oxymorphone can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Dimenhydrinate.Approved
DiphenhydramineThe metabolism of Oxymorphone can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Oxymorphone.Approved, Illicit
DoramectinThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Doxepin.Approved
DoxycyclineThe metabolism of Oxymorphone can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Oxymorphone.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Oxymorphone is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Oxymorphone.Approved, Illicit
DronedaroneThe metabolism of Oxymorphone can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Oxymorphone.Approved, Vet Approved
DrospirenoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Drospirenone.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Drotebanol.Experimental, Illicit
DuloxetineThe metabolism of Oxymorphone can be decreased when combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Oxymorphone.Approved
EcgonineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Oxymorphone is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Oxymorphone can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Efonidipine.Approved
EliglustatThe metabolism of Oxymorphone can be decreased when combined with Eliglustat.Approved
EluxadolineOxymorphone may increase the constipating activities of Eluxadoline.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Oxymorphone.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Oxymorphone can be decreased when it is combined with Enzalutamide.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Eplerenone.Approved
ErythromycinThe metabolism of Oxymorphone can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramOxymorphone may increase the serotonergic activities of Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Oxymorphone can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstazolamThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Oxymorphone.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Etacrynic acid.Approved
EthanolOxymorphone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Oxymorphone.Approved, Illicit, Withdrawn
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Oxymorphone.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ethotoin.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ethoxzolamide.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Oxymorphone.Approved
EtoperidoneOxymorphone may increase the serotonergic activities of Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Oxymorphone can be decreased when it is combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Oxymorphone.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Oxymorphone.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Flibanserin.Approved
FluconazoleThe metabolism of Oxymorphone can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe metabolism of Oxymorphone can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Oxymorphone.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Oxymorphone.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Oxymorphone.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Fluticasone Propionate.Approved
FluvoxamineThe metabolism of Oxymorphone can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Oxymorphone can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Oxymorphone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Oxymorphone can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Fospropofol.Approved, Illicit
FurazolidoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Furazolidone.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Oxymorphone can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Oxymorphone.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Oxymorphone is combined with gabapentin enacarbil.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Oxymorphone.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Glutethimide.Approved, Illicit
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Oxymorphone.Approved, Investigational, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Oxymorphone.Approved, Illicit, Withdrawn
HaloperidolThe metabolism of Oxymorphone can be decreased when combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Oxymorphone.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Heroin.Approved, Illicit
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Oxymorphone.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Hexobarbital.Approved
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Oxymorphone.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Hydracarbazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneOxymorphone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Oxymorphone.Approved, Illicit
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may increase the analgesic activities of Oxymorphone.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Oxymorphone.Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Oxymorphone.Approved
IdelalisibThe serum concentration of Oxymorphone can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Iloperidone.Approved
ImatinibThe metabolism of Oxymorphone can be decreased when combined with Imatinib.Approved
ImipramineThe metabolism of Oxymorphone can be decreased when combined with Imipramine.Approved
IndalpineOxymorphone may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Indapamide.Approved
IndinavirThe metabolism of Oxymorphone can be decreased when combined with Indinavir.Approved
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Oxymorphone.Approved
IproclozideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Iproclozide.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Iproniazid.Withdrawn
IsavuconazoniumThe metabolism of Oxymorphone can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Oxymorphone.Approved, Vet Approved
IsoniazidThe metabolism of Oxymorphone can be decreased when combined with Isoniazid.Approved
IsosorbideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Isosorbide.Approved
IsradipineThe metabolism of Oxymorphone can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Oxymorphone can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Oxymorphone can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ketobemidone.Approved
KetoconazoleThe metabolism of Oxymorphone can be decreased when combined with Ketoconazole.Approved, Investigational
KW-3902The risk or severity of adverse effects can be increased when Oxymorphone is combined with KW-3902.Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Oxymorphone.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Levomethadyl Acetate.Approved
LevomilnacipranOxymorphone may increase the serotonergic activities of Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Oxymorphone.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Oxymorphone.Approved, Vet Approved
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Oxymorphone.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Lofentanil.Illicit
LopinavirThe metabolism of Oxymorphone can be decreased when combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Oxymorphone.Approved
LorcaserinThe metabolism of Oxymorphone can be decreased when combined with Lorcaserin.Approved
LovastatinThe metabolism of Oxymorphone can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Oxymorphone.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Oxymorphone is combined with Lu AA21004.Investigational
LuliconazoleThe serum concentration of Oxymorphone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Oxymorphone can be increased when combined with Lumacaftor.Approved
LumefantrineThe metabolism of Oxymorphone can be decreased when combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Oxymorphone.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Maprotiline.Approved
MebanazineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Mebanazine.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Oxymorphone.Approved
MeclizineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Oxymorphone.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Melperone.Approved
MephedroneMephedrone may increase the analgesic activities of Oxymorphone.Investigational
MephentermineMephentermine may increase the analgesic activities of Oxymorphone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Oxymorphone.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Oxymorphone.Approved, Illicit
MersalylThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Mersalyl.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Oxymorphone.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Metaxalone.Approved
MethadoneThe metabolism of Oxymorphone can be decreased when combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineMethamphetamine may increase the analgesic activities of Oxymorphone.Approved, Illicit
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Oxymorphone.Approved
MethapyrileneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Oxymorphone.Approved
MethotrimeprazineOxymorphone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Oxymorphone.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Methyclothiazide.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Methylene blue.Investigational
MethylnaltrexoneThe risk or severity of adverse effects can be increased when Methylnaltrexone is combined with Oxymorphone.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Oxymorphone.Approved
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Oxymorphone.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Metolazone.Approved
MetoprololThe metabolism of Oxymorphone can be decreased when combined with Metoprolol.Approved, Investigational
MetyrosineOxymorphone may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Oxymorphone.Approved, Illicit
MifepristoneThe serum concentration of Oxymorphone can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranOxymorphone may increase the serotonergic activities of Milnacipran.Approved
MinaprineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Oxymorphone.Approved, Investigational
MirabegronThe metabolism of Oxymorphone can be decreased when combined with Mirabegron.Approved
MirtazapineOxymorphone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Oxymorphone can be decreased when it is combined with Mitotane.Approved
MMDAMMDA may increase the analgesic activities of Oxymorphone.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Moclobemide.Approved
ModafinilThe serum concentration of Oxymorphone can be decreased when it is combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Molindone.Approved
MoricizineMoricizine may increase the hypotensive activities of Oxymorphone.Approved, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Oxymorphone.Approved, Investigational
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when N-butylscopolammonium bromide is combined with Oxymorphone.Vet Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Oxymorphone.Approved, Investigational
NafcillinThe serum concentration of Oxymorphone can be decreased when it is combined with Nafcillin.Approved
NalbuphineNalbuphine may decrease the analgesic activities of Oxymorphone.Approved
NaloxegolThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Naloxegol.Approved
NaltrexoneThe therapeutic efficacy of Oxymorphone can be decreased when used in combination with Naltrexone.Approved, Investigational, Vet Approved
NefazodoneThe metabolism of Oxymorphone can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Oxymorphone can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Oxymorphone can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Oxymorphone can be increased when combined with Nevirapine.Approved
NialamideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Nialamide.Withdrawn
NicardipineThe metabolism of Oxymorphone can be decreased when combined with Nicardipine.Approved
NilotinibThe metabolism of Oxymorphone can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Nitrous oxide.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Nortriptyline.Approved
NVA237The risk or severity of adverse effects can be increased when NVA237 is combined with Oxymorphone.Investigational
OctamoxinThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Octamoxin.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Oxymorphone.Approved, Investigational
OlaparibThe metabolism of Oxymorphone can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Oxymorphone.Approved
OpiumThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Opium.Approved, Illicit
OrphenadrineOxymorphone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Oxymorphone can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Oxymorphone.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Oxymorphone.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Oxymorphone.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Oxymorphone.Approved, Illicit, Investigational
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Oxymorphone.Approved
PalbociclibThe serum concentration of Oxymorphone can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Paliperidone.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Oxymorphone.Approved
PanobinostatThe serum concentration of Oxymorphone can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydeOxymorphone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
PargylineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Pargyline.Approved
ParoxetineThe metabolism of Oxymorphone can be decreased when combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Oxymorphone can be decreased when it is combined with Peginterferon alfa-2b.Approved
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Oxymorphone.Approved
PentazocinePentazocine may decrease the analgesic activities of Oxymorphone.Approved, Vet Approved
PentobarbitalThe metabolism of Oxymorphone can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Oxymorphone.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Oxymorphone.Approved
PerazineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Oxymorphone.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Oxymorphone.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Phenelzine.Approved
PheniprazineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Pheniprazine.Withdrawn
PhenobarbitalThe metabolism of Oxymorphone can be increased when combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Phenoxyethanol.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Phenoxypropazine.Withdrawn
PhenterminePhentermine may increase the analgesic activities of Oxymorphone.Approved, Illicit
PhenytoinThe metabolism of Oxymorphone can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Oxymorphone.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Pipamperone.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Oxymorphone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Pipotiazine.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Oxymorphone.Approved
PiretanideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Piretanide.Experimental
PiritramideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Piritramide.Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Pirlindole.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Pivhydrazine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Pizotifen.Approved
PolythiazideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Oxymorphone can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PotassiumThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Potassium.Approved
Potassium CitrateThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Potassium Citrate.Approved, Vet Approved
PramipexoleOxymorphone may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Oxymorphone.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Oxymorphone.Approved
PrimidoneThe metabolism of Oxymorphone can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Oxymorphone.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Oxymorphone.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Oxymorphone.Approved
PromazineThe metabolism of Oxymorphone can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Promethazine.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Oxymorphone.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Oxymorphone.Approved, Vet Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Oxymorphone.Vet Approved
PropiverineThe risk or severity of adverse effects can be increased when Propiverine is combined with Oxymorphone.Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Oxymorphone.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when Oxymorphone is combined with PSD502.Investigational
PseudoephedrinePseudoephedrine may increase the analgesic activities of Oxymorphone.Approved
QuazepamThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Quetiapine.Approved
QuinethazoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Quinethazone.Approved
QuinidineThe metabolism of Oxymorphone can be decreased when combined with Quinidine.Approved
QuinineThe metabolism of Oxymorphone can be decreased when combined with Quinine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ramelteon.Approved, Investigational
RamosetronOxymorphone may increase the constipating activities of Ramosetron.Approved
RanolazineThe metabolism of Oxymorphone can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Oxymorphone.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Oxymorphone.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Oxymorphone.Approved
RifabutinThe metabolism of Oxymorphone can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Oxymorphone can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Oxymorphone can be increased when combined with Rifapentine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Oxymorphone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ritanserin.Investigational
RitobegronRitobegron may increase the analgesic activities of Oxymorphone.Investigational
RitonavirThe metabolism of Oxymorphone can be decreased when combined with Ritonavir.Approved, Investigational
RolapitantThe metabolism of Oxymorphone can be decreased when combined with Rolapitant.Approved
RolofyllineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Rolofylline.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Romifidine.Vet Approved
RopiniroleOxymorphone may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Oxymorphone.Approved
RotigotineOxymorphone may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Oxymorphone.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Oxymorphone is combined with S-Ethylisothiourea.Experimental
SafrazineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Safrazine.Withdrawn
Sage 547The risk or severity of adverse effects can be increased when Oxymorphone is combined with Sage 547.Investigational
SaquinavirThe metabolism of Oxymorphone can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Scopolamine.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Oxymorphone.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Oxymorphone.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Selegiline.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Sertindole.Approved, Withdrawn
SertralineThe metabolism of Oxymorphone can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Oxymorphone can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Oxymorphone can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Oxymorphone can be increased when it is combined with Simeprevir.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Oxymorphone.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Oxymorphone.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Oxymorphone can be decreased when it is combined with St. John&#39;s Wort.Nutraceutical
StiripentolThe serum concentration of Oxymorphone can be increased when it is combined with Stiripentol.Approved
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Oxymorphone.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Oxymorphone.Approved, Investigational
SulfisoxazoleThe metabolism of Oxymorphone can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Oxymorphone.Approved
SuvorexantOxymorphone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Oxymorphone.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Tasimelteon.Approved
TelaprevirThe metabolism of Oxymorphone can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Oxymorphone can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Oxymorphone.Approved
TerbinafineThe metabolism of Oxymorphone can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Tetrodotoxin.Investigational
ThalidomideOxymorphone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Theobromine.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Oxymorphone.Approved, Vet Approved
ThiethylperazineThiethylperazine may increase the hypotensive activities of Oxymorphone.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Oxymorphone.Approved, Vet Approved
ThioridazineThe metabolism of Oxymorphone can be decreased when combined with Thioridazine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Tiapride.Investigational
TiclopidineThe metabolism of Oxymorphone can be decreased when combined with Ticlopidine.Approved
TicrynafenThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ticrynafen.Withdrawn
TiletamineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Tiletamine.Vet Approved
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Oxymorphone.Approved
TipranavirThe metabolism of Oxymorphone can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Oxymorphone can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Tolcapone.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Toloxatone.Approved
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Oxymorphone.Approved, Investigational
TolvaptanThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Tolvaptan.Approved
TopiramateThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Torasemide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Oxymorphone.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Oxymorphone.Approved, Investigational
TriamtereneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Oxymorphone.Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Oxymorphone.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Oxymorphone.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Oxymorphone.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Oxymorphone.Approved
TrimipramineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Triprolidine.Approved
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Oxymorphone.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Oxymorphone.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Oxymorphone.Approved
Uc1010The risk or severity of adverse effects can be increased when Oxymorphone is combined with Uc1010.Investigational
UlaritideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ularitide.Investigational
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Oxymorphone.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Oxymorphone.Approved, Investigational
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Oxymorphone.Approved
VenlafaxineThe metabolism of Oxymorphone can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Oxymorphone can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Vigabatrin.Approved
VoriconazoleThe metabolism of Oxymorphone can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Oxymorphone.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ziconotide.Approved
ZimelidineOxymorphone may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Oxymorphone can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Zolazepam.Vet Approved
ZolpidemOxymorphone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

Bao-Shan Huang, Yansong Lu, Ben-Yi Ji, Aris P Christodoulou, “Preparation of oxymorphone from morphine.” U.S. Patent US5922876, issued May, 1992.

US5922876
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (9.95 MB)
MSDSDownload (133 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9934
Blood Brain Barrier+0.9382
Caco-2 permeable+0.7798
P-glycoprotein substrateSubstrate0.9112
P-glycoprotein inhibitor INon-inhibitor0.8887
P-glycoprotein inhibitor IINon-inhibitor0.9734
Renal organic cation transporterNon-inhibitor0.5585
CYP450 2C9 substrateNon-substrate0.8014
CYP450 2D6 substrateSubstrate0.8105
CYP450 3A4 substrateSubstrate0.7439
CYP450 1A2 substrateNon-inhibitor0.8796
CYP450 2C9 inhibitorNon-inhibitor0.9459
CYP450 2D6 inhibitorNon-inhibitor0.7168
CYP450 2C19 inhibitorNon-inhibitor0.8455
CYP450 3A4 inhibitorNon-inhibitor0.9219
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9812
Ames testNon AMES toxic0.6663
CarcinogenicityNon-carcinogens0.9635
BiodegradationNot ready biodegradable0.9758
Rat acute toxicity2.9920 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9345
hERG inhibition (predictor II)Non-inhibitor0.9374
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
LiquidIntramuscular; Intravenous; Subcutaneous1.5 mg
SuppositoryRectal5 mg
InjectionIntramuscular; Intravenous; Subcutaneous1 mg/mL
TabletOral20 mg/1
Tablet, extended releaseOral10 mg
Tablet, extended releaseOral20 mg
Tablet, extended releaseOral40 mg
Tablet, extended releaseOral5 mg
Tablet, film coated, extended releaseOral10 mg/1
Tablet, film coated, extended releaseOral40 mg/1
Tablet, film coated, extended releaseOral5 mg/1
TabletOral10 mg/1
TabletOral5 mg/1
Tablet, film coated, extended releaseOral15 mg/1
Tablet, film coated, extended releaseOral20 mg/1
Tablet, film coated, extended releaseOral30 mg/1
Tablet, film coated, extended releaseOral7.5 mg/1
Tablet, extended releaseOral10 mg/1
Tablet, extended releaseOral15 mg/1
Tablet, extended releaseOral20 mg/1
Tablet, extended releaseOral30 mg/1
Tablet, extended releaseOral40 mg/1
Tablet, extended releaseOral5 mg/1
Tablet, extended releaseOral7.5 mg/1
Prices
Unit descriptionCostUnit
Opana er 40 mg tablet21.82USD tablet
Opana er 30 mg tablet17.39USD tablet
Opana ER 40 mg 12 Hour tablet12.42USD tablet
Opana er 20 mg tablet12.12USD tablet
Opana ER 30 mg 12 Hour tablet9.76USD tablet
Opana er 15 mg tablet9.26USD tablet
Opana ER 20 mg 12 Hour tablet7.17USD tablet
Opana ER 15 mg 12 Hour tablet5.82USD tablet
Opana er 5 mg tablet5.53USD tablet
Opana ER 10 mg 12 Hour tablet4.4USD tablet
Opana er 10 mg tablet3.95USD tablet
Opana ER 7.5 mg 12 Hour tablet3.3USD tablet
Numorphan 1 mg/ml ampul3.13USD ml
Opana er 7.5 mg tablet3.0USD tablet
Opana ER 5 mg 12 Hour tablet2.3USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5662933 No1993-09-092013-09-09Us
US7276250 No2003-02-042023-02-04Us
US7851482 No2009-07-102029-07-10Us
US8075872 No2003-11-202023-11-20Us
US8114383 No2004-08-082024-08-08Us
US8192722 No2005-09-152025-09-15Us
US8309060 No2003-11-202023-11-20Us
US8309122 No2003-02-042023-02-04Us
US8329216 No2003-02-042023-02-04Us
US8808737 No2007-06-212027-06-21Us
US8871779 No2009-11-222029-11-22Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point248-249 °CPhysProp
water solubility2.4E+004 mg/LNot Available
logP0.83HANSCH,C ET AL. (1995)
pKa8.17SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility25.6 mg/mLALOGPS
logP1.26ALOGPS
logP0.78ChemAxon
logS-1.1ALOGPS
pKa (Strongest Acidic)7.34ChemAxon
pKa (Strongest Basic)10.93ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area70 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity79.56 m3·mol-1ChemAxon
Polarizability30.77 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0udl-7932000000-89141254d526ca629dacView in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassMorphinans
Sub ClassNot Available
Direct ParentMorphinans
Alternative Parents
Substituents
  • Morphinan
  • Benzylisoquinoline
  • Phenanthrene
  • Isoquinolone
  • Tetralin
  • Benzofuran
  • Aralkylamine
  • Cyclohexanone
  • Alkyl aryl ether
  • Benzenoid
  • Piperidine
  • Tertiary alcohol
  • Cyclic alcohol
  • Tertiary aliphatic amine
  • Tertiary amine
  • Ketone
  • 1,2-aminoalcohol
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Voltage-gated calcium channel activity
Specific Function:
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociati...
Gene Name:
OPRM1
Uniprot ID:
P35372
Molecular Weight:
44778.855 Da
References
  1. Spetea M, Nevin ST, Hosztafi S, Ronai AZ, Toth G, Borsodi A: Affinity profiles of novel delta-receptor selective benzofuran derivatives of non-peptide opioids. Neurochem Res. 1998 Sep;23(9):1211-6. [PubMed:9712193 ]
  2. Lemberg KK, Kontinen VK, Siiskonen AO, Viljakka KM, Yli-Kauhaluoma JT, Korpi ER, Kalso EA: Antinociception by spinal and systemic oxycodone: why does the route make a difference? In vitro and in vivo studies in rats. Anesthesiology. 2006 Oct;105(4):801-12. [PubMed:17006080 ]
  3. Chamberlin KW, Cottle M, Neville R, Tan J: Oral oxymorphone for pain management. Ann Pharmacother. 2007 Jul;41(7):1144-52. Epub 2007 Jun 26. [PubMed:17595308 ]
  4. Halimi G, Devaux C, Clot-Faybesse O, Sampol J, Legof L, Rochat H, Guieu R: Modulation of adenosine concentration by opioid receptor agonists in rat striatum. Eur J Pharmacol. 2000 Jun 16;398(2):217-24. [PubMed:10854833 ]
  5. Gardell LR, King T, Ossipov MH, Rice KC, Lai J, Vanderah TW, Porreca F: Opioid receptor-mediated hyperalgesia and antinociceptive tolerance induced by sustained opiate delivery. Neurosci Lett. 2006 Mar 20;396(1):44-9. Epub 2005 Dec 15. [PubMed:16343768 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurot...
Gene Name:
OPRD1
Uniprot ID:
P41143
Molecular Weight:
40368.235 Da
References
  1. Chamberlin KW, Cottle M, Neville R, Tan J: Oral oxymorphone for pain management. Ann Pharmacother. 2007 Jul;41(7):1144-52. Epub 2007 Jun 26. [PubMed:17595308 ]
  2. Ananthan S, Khare NK, Saini SK, Seitz LE, Bartlett JL, Davis P, Dersch CM, Porreca F, Rothman RB, Bilsky EJ: Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone]. J Med Chem. 2004 Mar 11;47(6):1400-12. [PubMed:14998329 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Gronlund J, Saari TI, Hagelberg NM, Neuvonen PJ, Olkkola KT, Laine K: Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone. Br J Clin Pharmacol. 2010 Jul;70(1):78-87. doi: 10.1111/j.1365-2125.2010.03653.x. [PubMed:20642550 ]
  2. Samer CF, Daali Y, Wagner M, Hopfgartner G, Eap CB, Rebsamen MC, Rossier MF, Hochstrasser D, Dayer P, Desmeules JA: The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. Br J Pharmacol. 2010 Jun;160(4):907-18. doi: 10.1111/j.1476-5381.2010.00673.x. [PubMed:20590587 ]
  3. Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen LY, Shen DD: Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther. 2006 May;79(5):461-79. [PubMed:16678548 ]
  4. Adams M, Pieniaszek HJ Jr, Gammaitoni AR, Ahdieh H: Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways. J Clin Pharmacol. 2005 Mar;45(3):337-45. [PubMed:15703368 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Gronlund J, Saari TI, Hagelberg NM, Neuvonen PJ, Olkkola KT, Laine K: Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone. Br J Clin Pharmacol. 2010 Jul;70(1):78-87. doi: 10.1111/j.1365-2125.2010.03653.x. [PubMed:20642550 ]
  2. Samer CF, Daali Y, Wagner M, Hopfgartner G, Eap CB, Rebsamen MC, Rossier MF, Hochstrasser D, Dayer P, Desmeules JA: The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. Br J Pharmacol. 2010 Jun;160(4):907-18. doi: 10.1111/j.1476-5381.2010.00673.x. [PubMed:20590587 ]
  3. Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen LY, Shen DD: Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther. 2006 May;79(5):461-79. [PubMed:16678548 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 08, 2016 11:46